<strike id="uxnyq"></strike>
      <tr id="uxnyq"></tr>

             
            E-mail: sales@hlsw-bio.com
           
             
            +86-0510-85629785
             
            sales@hlsw-bio.com
          info@hlsw-bio.com
             
            No.138,Mashan Meiliang Road,Hubin, Wuxi,Jiangsu Province,China
           
             
            News Your location: Home -News
           
             
             
          Raw material medicine in crossroads

          Views:7814      origin:Administrator      Add time:2014/9/28
          ..........................................................................................................................................................................................................................................

          Some people said that, the reform is never persecuted, at present, production enterprises of raw materials into a corner, not changed to the extent not, from another point of view, which to some extent, has accelerated the pace of raw material medicine industry upgrading and transformation.
          The traditional bulk raw material market prosperity in more than a decade later, start collapsing last year. The export of traditional bulk raw material medicine early China into the bottlenecks, and the new growth point has not yet fully formed, the export situation is grim.
          With the domestic environmental policy tightening, limiting the clinical use of antibiotics, the traditional bulk raw material demand will decline in the domestic trouble and foreign invasion, are a test of raw material medicine production enterprises. For these enterprises, has reached a crucial moment to reflect on, the adjustment of industrial structure and enterprise strategy.
          The history of the most stringent 'limit resistance to' issued, for the fierce competition, product homogenization of serious domestic antibiotic production industry, will "fight" more tragic. "Limit resistance to" shock wave extension in the industrial chain, the upstream antibiotic raw materials enterprises by the most powerful earthquake.
          It is understood, the result of market competition make the bulk raw material production has been concentrated in a few large pharmaceutical companies. Such as penicillin and derivative products more than 90% production concentrated in the North China pharmaceutical, Harbin Pharmaceutical Group, Lukang Pharmaceutical, Shijiazhuang pharmaceutical enterprises 4 hands; 98% of the vitamin C production is concentrated in the Northeast Pharmaceutical, Shijiazhuang pharmaceutical, North China Pharmaceutical and Jiangshan pharmaceutical enterprises 4; while the Xinhua Pharmaceutical is antipyretic analgesic category of raw material medicine production enterprises in China the biggest.








          Prev:Raw material medicine serious excess capacity

          Next:No information!
                 
            Add:No.138,Mashan Meiliang Road,Hubin, Wuxi,Jiangsu Province,China
          Tel:+86-0510-85629785   Fax:+86-0510-85625359   E-mail:sales@hlsw-bio.com info@hlsw-bio.com
          Copyright (c) Wuxi Helen Biotechnology Co., Ltd. All rights reserved    备案号:苏ICP备16043161号
           
           
          H无码无删减动漫在线观看,99精品国产在热久久,大香伊蕉在人线免费视频,国产又色又爽又黄的视频在线
            <strike id="uxnyq"></strike>
            <tr id="uxnyq"></tr>